- Home
- LAW vs TLSA Comparison
LAW vs TLSA Comparison
Compare LAW & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAW
- TLSA
- Stock Information
- Founded
- LAW 2013
- TLSA 2013
- Country
- LAW United States
- TLSA United Kingdom
- Employees
- LAW N/A
- TLSA N/A
- Industry
- LAW Computer Software: Prepackaged Software
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- LAW Technology
- TLSA Health Care
- Exchange
- LAW Nasdaq
- TLSA Nasdaq
- Market Cap
- LAW 249.3M
- TLSA 240.0M
- IPO Year
- LAW 2021
- TLSA 2000
- Fundamental
- Price
- LAW $7.09
- TLSA $1.75
- Analyst Decision
- LAW Buy
- TLSA
- Analyst Count
- LAW 2
- TLSA 0
- Target Price
- LAW $7.75
- TLSA N/A
- AVG Volume (30 Days)
- LAW 156.6K
- TLSA 233.3K
- Earning Date
- LAW 11-05-2025
- TLSA 01-01-0001
- Dividend Yield
- LAW N/A
- TLSA N/A
- EPS Growth
- LAW N/A
- TLSA N/A
- EPS
- LAW N/A
- TLSA N/A
- Revenue
- LAW $152,677,000.00
- TLSA N/A
- Revenue This Year
- LAW $7.13
- TLSA N/A
- Revenue Next Year
- LAW $6.25
- TLSA N/A
- P/E Ratio
- LAW N/A
- TLSA N/A
- Revenue Growth
- LAW 6.33
- TLSA N/A
- 52 Week Low
- LAW $3.31
- TLSA $0.63
- 52 Week High
- LAW $7.35
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- LAW 59.50
- TLSA 43.56
- Support Level
- LAW $5.92
- TLSA $1.69
- Resistance Level
- LAW $7.24
- TLSA $2.04
- Average True Range (ATR)
- LAW 0.36
- TLSA 0.13
- MACD
- LAW 0.04
- TLSA -0.01
- Stochastic Oscillator
- LAW 82.03
- TLSA 26.51
About LAW CS Disco Inc.
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.